Loading…
← CockpitCompetitor Analysis › TYRA Tyra Bioscience, IncOpen in the cockpit ↗

Tyra Bioscience, IncTYRACompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Develops precision small-molecule inhibitors targeting FGFR genetic alterations in cancer and genetic skeletal disorders.

Momentum weak 21
Mkt cap
$1.35B
US dollars, full cap
Free float
77%
of shares outstanding
$/day
$12.8M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 8.3%
Hurdle
n/a
no reverse DCF
Next earnings
126 days
24 Mar 2027
Close · USD$19.61
1D+0.2%
1W-6.5%
1M-4.2%
3M-23.7%
6M-41.3%
YTD-25.4%
1Y+23.3%
ATR %5.9%
Beta0.53
52w lowhigh51.8% off high

What Tyra Bioscience does

Develops precision small-molecule inhibitors targeting FGFR genetic alterations in cancer and genetic skeletal disorders.

Has no product on the market, so no sales; it is funded by money raised from investors and spends it on clinical trials of its FGFR drugs. Its approach is to design drugs that keep working when cancer cells mutate to resist older ones. It went public in 2023.

Products and services

  • TYRA-300 (achondroplasia, bladder cancer)
  • TYRA-200 (cholangiocarcinoma)

Customers

  • Oncologists/geneticists (post-approval)

Where it sits in the supply chain

  • Health Care
  • Biotechnology
  • FGFR-targeted precision medicine

What could go right

  • Dual oncology/genetic disease pipeline optionality
  • Pivotal trial data readouts

What could go wrong

  • Clinical trial failure risk
  • Competitive FGFR-targeted therapy field

Moat: none (IP / patents, process know-how). Proprietary structure-based platform designs FGFR inhibitors resistant to resistance mutations, but is clinical-stage.

Headquarters: Carlsbad, California, US · Founded: 2018 · Employees: 87

Named competitors

Tyra Bioscience at a glance

Size Tyra Bioscience (TYRA) is a United States Health Care company (Biotechnology) with a market value of $1.35B, the 2040th largest of 3,085 United States companies the cockpit tracks. Shares closed at $19.61 on 18 Nov 2026.

Performance Over six months the shares fell 41.3%, against -20.3% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd lowest of 20 in its peer set.

Short interest Short interest is 14.3% of the free float (30 Oct 2026).

Next results Next results expected around 24 Mar 2027 (exchange calendar; dates can move).

Relative performance

608010012021 May 202621 Aug 202618 Nov 2026Peer median 80TYRA 59
Six months, rebased to 100: Tyra Bioscience against the median of its 20 peers (local-currency closes).

Tyra Bioscience financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$0$0$0$0$0
Revenue growth—————
Gross profit-$538,000-$546,000-$519,000-$353,000-$296,000
EBITDA-$182M-$132M-$104M-$79.6M-$58.6M
Net income-$170M-$120M-$86.5M-$69.1M-$55.3M
Free cash flow-$120M-$95.3M-$70.4M-$50.9M-$50.8M
Capital expenditure$301,000$141,000$664,000$770,000$559,000
Total debt$5.46M$5.81M$6.22M$6.50M$2.62M

Quarterly statements and history in the cockpit →

Tyra Bioscience competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%-25%0%+25%+50%6185GENBNUVB4588NVAXANABTSHAABSIQURE688105IMCR688765MSBTYRA6-month return →1-month return →
Up and to the right = strong over both horizons. Tyra Bioscience is the large dot.

Tyra Bioscience competitors and peer comparison

Head to head with its named competitors (TYRA vs BBIO vs INCY)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Tyra Bioscience TYRA$1.35B-41%n/an/an/an/a
BridgeBio Pharma BBIO$15.2B+14%+167%-37%19.1×n/a
Incyte INCY$24.0B+21%+25%12%3.4×14.2%

How Tyra Bioscience compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Tyra Bioscience against its 20 peers (data as of 18 Nov 2026)
MeasureTYRAPeer medianRank in peer set
1-month return-4.2%-15.3%6th highest of 21
6-month return-41.3%-20.3%2nd lowest of 20
Distance from 52-week high-51.8%-47.0%7th lowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Tyra Bioscience TYRAUnited States$1.35B-41%n/an/an/an/an/a
CanSino Biologics 6185.HKHong Kong$1.36B-23%+36%-4%6.8×n/an/a
Generate Biomedicines GENBUnited States$1.34B-20%+56%-737%31.7×n/an/a
Intellia Therapeutics NTLAUnited States$1.37B-20%-8%-821%21.3×n/an/a
Nuvation Bio NUVBUnited States$1.34B-16%+654%-61%5.7×n/an/a
Oncolys BioPharma 4588.TJapan$1.37B+181%+1,749%-295%408.9×n/an/a
Rapport Therapeutics RAPPUnited States$1.39B-34%n/a-838%50.1×n/an/a
Zhuhai Trinomab Pharmaceutical 688806.SSChina$1.32Bn/a+238%-1,196%164.8×n/an/a
Novavax NVAXUnited States$1.31B-14%-61%-17%2.4×n/an/a
AnaptysBio ANABUnited States$1.40B-22%+13%62%7.9×0.5%+25.6%
Taysha Gene Therapies TSHAUnited States$1.30B-27%-13%-2,998%170.1×n/an/a
Absci ABSIUnited States$1.41B+65%-47%-9,155%835.7×n/an/a
uniQure QUREUnited States$1.42B-17%+28%-1,027%65.4×n/an/a
Nanjing Vazyme Biotech 688105.SSChina$1.42B+25%+16%-5%4.9×39.4%-2.5%
Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCRUnited States$1.44B-7%+13%-7%2.3×n/an/a
Wuhan Healthgen Biotechnology 688765.SSChina$1.46B-51%+90%-297%205.0×n/an/a
UroGen Pharma URGNUnited States$1.46B-1%+159%-12%6.3×n/an/a
Hualan Biological Vaccine 301207.SZChina$1.25B-29%-28%-7%9.0×33.2%-13.1%
Fujian Haixi Pharmaceuticals 2637.HKHong Kong$1.47B-32%+25%33%n/an/an/a
Pacific Shuanglin Bio-pharmacy 000403.SZChina$1.24B-21%+1%10%3.5×n/an/a
Mesoblast MSB.AXAustralia$1.49B-17%+556%-43%12.8×n/an/a

Questions

Who are Tyra Bioscience's main competitors?
Named competitors: BridgeBio Pharma (BBIO), Incyte (INCY). The cockpit's measured peer set (industry) also includes CanSino Biologics (6185.HK), Generate Biomedicines (GENB), Intellia Therapeutics (NTLA), Nuvation Bio (NUVB), Oncolys BioPharma (4588.T), Rapport Therapeutics (RAPP).
How has Tyra Bioscience stock performed?
Over six months to 18 Nov 2026 the shares returned -41.3% against -20.3% for the median peer; over one year +23.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.